Literature DB >> 8248817

Bone metastases as the presenting manifestation of rhabdomyosarcoma in childhood.

L G Shapeero1, D Couanet, D Vanel, L V Ackerman, M J Terrier-Lacombe, F Flamant, G Contesso, J Lumbroso.   

Abstract

Rarely, rhabdomyosarcoma can present with bone pain and bone lesions on radiographs without evidence of a primary tumor. Of 428 children with biopsy-proven rhabdomyosarcoma, four presented with radiographic evidence of bone metastases, but no primary tumor was found on subsequent evaluation. On radiographs, these metastases, located most commonly in the metaphyses of the extremities and in the spine, displayed a destructive or diffusely permeative pattern without sclerotic margins and mimicked the more common neuroblastoma. One patient also had diaphyseal cortical lytic metastases of the tibia. Radiographs defined metastases of the extremities better than the correlative bone scans. In the spine, on T2-weighted magnetic resonance (MR) images, metastases displayed high signal intensity which contrasted with the low-signal-intensity marrow in these pediatric patients. On histopathologic examination, metastatic rhabdomyosarcoma was composed of small cells of variable size, shape, and growth pattern similar to other round cell tumors. A positive desmin immunohistochemical test helped to establish the diagnosis. The radiologist, pathologist, and clinician should be aware of this unusual presentation of rhabdomyosarcoma so that suitable immunohistochemical tests are performed and appropriate chemotherapy given.

Entities:  

Mesh:

Year:  1993        PMID: 8248817     DOI: 10.1007/bf00538446

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  25 in total

1.  False negative bone scans in neuroblastoma metastatic to the ends of long bones.

Authors:  R A Kaufman; J H Thrall; J W Keyes; M L Brown; J F Zakem
Journal:  AJR Am J Roentgenol       Date:  1978-01       Impact factor: 3.959

2.  Frequency and significance of bone marrow involvement by metastatic solid tumors.

Authors:  R M Anner; B Drewinko
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

3.  Childhood acute lymphocytic leukemia. Initial radiological bone involvement and prognosis.

Authors:  R J Aur; H W Westbrook; W Riggs
Journal:  Am J Dis Child       Date:  1972-11

4.  Alveolar rhabdomyosarcoma. An analysis of 110 cases.

Authors:  F M Enzinger; M Shiraki
Journal:  Cancer       Date:  1969-07       Impact factor: 6.860

5.  Consistent chromosomal translocation in alveolar rhabdomyosarcoma.

Authors:  C Turc-Carel; S Lizard-Nacol; E Justrabo; M Favrot; T Philip; E Tabone
Journal:  Cancer Genet Cytogenet       Date:  1986-01-15

6.  Hypercalcemia and elevated serum parathyroid hormone level in association with rhabdomyosarcoma.

Authors:  I Elomaa; V P Lehto; R K Selander
Journal:  Arch Pathol Lab Med       Date:  1984-09       Impact factor: 5.534

7.  Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study.

Authors:  F B Ruymann; W A Newton; A H Ragab; M H Donaldson; M Foulkes
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

8.  Alveolar rhabdomyosarcoma: a cytogenetic and correlated cytological and histological study.

Authors:  T Seidal; J Mark; B Hagmar; L Angervall
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1982-09

9.  Comparison between x-ray and bone scan detection of bone metastases in patients with rhabdomyosarcoma.

Authors:  F F Quddus; D Espinola; S S Kramer; B G Leventhal
Journal:  Med Pediatr Oncol       Date:  1983

10.  Bone metastases from Ewing's sarcoma radiologically recapitulate the features of a primary Ewing's tumour.

Authors:  P N Plowman
Journal:  Clin Radiol       Date:  1989-09       Impact factor: 2.350

View more
  1 in total

1.  Rhabdomyosarcoma With Diffuse Bone Marrow Metastases.

Authors:  Daniel Huang; Pankaj Watal; Dennis Drehner; Deeksha Dhar; Tushar Chandra
Journal:  Cureus       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.